- •Premature coronary heart disease (CHD) is uncommon in young women.
- •Common causes of premature CHD include familial hypercholesterolemia, diabetes, and heavy smoking.
- •This case adds high lipoprotein(a) levels as another potential cause of premature CHD.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Ischemic stroke in a young adult with extremely elevated lipoprotein(a): a case report and review of literature.J Clin Lipidol. 2016; 10: 1266-1271
- Factors associated with coronary artery disease in young population (age ≤ 40): analysis with 217 cases.Med Sci J. 2014; 1: 38-42
- Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers.PLoS One. 2014; 9: e114519
- Oxidized phospholipids and lipoprotein-associated phospholipase A2 as important determinants of Lp(a) functionality and pathophysiological role.J Biomed Res. 2018; 32: 13-22
- A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies.J Am Coll Cardiol. 2017; 69: 692-711
- Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions.J Lipid Res. 2012; 53: 2773-2790
- Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the copenhagen city heart study.Circulation. 2008; 117: 176-184
- Myocardial infarction in young adults under 30 years: risk factors and clinical course.Clin Cardiol. 1987; 10: 9-15
- Acute myocardial infarction in the young--The University of Michigan experience.Am Heart J. 2002; 143: 56-62
- Atherosclerosis in the young: a virulent disease.Surgery. 1984; 96: 863-869
- Pro(a)LiFe Study Group*. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study.Circulation. 2013; 128: 2567-2576
- Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: findings gathered from more than 36,000 treatments at one center in Germany.Atheroscler Suppl. 2015; 18: 154-162
- PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.J Lipid Res. 2016; 57: 1086-1096
- Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk.Curr Opin Endocrinol Diabetes Obes. 2016; 23: 157-164